Study Published in Child and Adolescent Psychiatry and Mental Health Demonstrated Once-Daily Vyvanse(R) (lisdexamfetamine dimesylate) CII Provided Significant Improvement of ADHD Symptoms for Children at 13 Hours After Administration

... with significant improvement in behavior and attention in children at each time point measured, with ... compared with placebo as measured by SKAMP attention (SKAMP-A), and Permanent Product Measure of ... physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human ...

Study Showed VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Significant Efficacy at 14 Hours After Administration in Adults with ADHD in an Adult Simulated Workplace Environment

... workplace environment study in adults with attention Deficit Hyperactivity Disorder (ADHD). VYVANSE ... in tests and activities that require a level of attention needed in many workplace settings. The efficacy ... physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human ...

FDA Approves Labeling Change for VYVANSE(R) (lisdexamfetamine dimesylate) CII to Include Supplementary Clinical Data Supporting Efficacy at 13 Hours Postdose in Children Aged 6 to 12 with ADHD

... to the prescribing information for its once-daily attention Deficit Hyperactivity Disorder (ADHD) treatment ... compared with placebo as measured by SKAMP attention (SKAMP-A), and Permanent Product Measure of ... physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human ...

Celebrity Designer Ty Pennington to Host 10th Annual 'ADHD Experts on Call' Program

... ADHD Experts to Answer Questions about attention Deficit Hyperactivity ... said David Goodman, M.D., director of the Adult attention Deficit Disorder Center of Maryland and assistant ... physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human ...

Shire Re-Launches ADHDSupport.com, a Virtual Road Map Providing Information, Tools and Practical Tips About Attention Deficit Hyperactivity Disorder (ADHD)

... and patients with tools and resources about attention Deficit Hyperactivity Disorder (ADHD). The newly ... expert, former president and CEO of the national attention Deficit Disorder Association (ADDA), psychologist ... conferences this year, such as the 13th annual attention Deficit Disorder Association (ADDA) national ...

FDA Approves VYVANSE(TM) (lisdexamfetamine dimesylate), the First and Only Once-Daily Prodrug Stimulant to Treat ADHD in Adults

... dimesylate), for the treatment of attention Deficit Hyperactivity Disorder (ADHD) in adults. ... School of Medicine and director of the Adult attention Deficit Disorder Center of Maryland. "The good ... physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human ...

Celebrity Designer Ty Pennington to Host 'ADHD Experts on Call' Program

... Leading ADHD Experts to Answer Questions about attention Deficit Hyperactivity ... to ask questions and learn more about attention Deficit Hyperactivity Disorder (ADHD) from some ... physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human ...

Publication of Shire plc's Annual Report 2008

... the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and ... the entrance of generic competitors for ADDERALL XR or other leading attention deficit and hyperactivity disorder ('ADHD') medications could impact the ...

Shire Announces Opening of Office in Japan

... in the world.[1] Shire currently focuses its business on the areas of attention deficit and hyperactivity disorder (ADHD), gastrointestinal (GI) and human ... the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT) ...

Shire to Enter European ADHD Market With the Acquisition of EQUASYM(R) IR and XL

... (excluding the USA, Canada and Barbados) used for the treatment of attention Deficit Hyperactivity Disorder (ADHD). EQUASYM XL is approved and ... the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and ...

Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion

... the third quarter of 2009. VYVANSE - for use in the treatment of attention deficit and hyperactivity disorder ("ADHD") in children in the European ... the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder ("ADHD"), human genetic therapies ...

Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009

... will have an immediate positive impact on our revenue growth. Because our attention is no longer being diverted by the demands of arbitration procedures, we believe that we can return our attention to growing Genesis and developing our Hongrui purchase." The ...

Developing a Safer and More Effective Way to Deliver Rabies Antibodies

... antibodies to protect people exposed to the rabies virus. Medical attention for a person exposed to rabies is a two-step procedure. First, rabies ... week of vaccination so RIG is essential at the first stage of medical attention before a person develops their own antibodies from vaccine. There ...

For nano, religion in US dictates a wary view

... due to the fact that mainstream media are only now beginning to pay closer attention to the issue. There has been a lot of elite discussion in Washington, ... has not had that catalytic moment, that key event that draws public attention to the issue." ...

Shire's New Product Portfolio Delivers Strong Quarterly Performance

... Update on Current Portfolio VYVANSE(R) (lisdexamfetamine dimesylate) - attention Deficit and Hyperactivity Disorder ("ADHD") - The launch of VYVANSE ... the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) ...

A need for improved efficiency in nanomanufacturing

... Yale University School of Forestry & Environmental Studies. "To date, most attention has focused on the possible toxic effects of exposure to nanoparticles and ... arising from the production technologies used to make nanomaterials need attention as well." One study, by Vikas Khanna and colleagues at the Ohio State ...

Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade.

... the US and the EU in 2010. VYVANSE(TM) (lisdexamfetamine dimesylate) - attention Deficit and Hyperactivity Disorder ("ADHD") - On April 23, 2008 Shire ... the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT) ...

Kansas Breaks Into Top 10 in the Nation in Biotech Strength

... positive showing in other recent national reports that also brought attention to the state's areas of bioscience strength, increases in R&D funding, and ... Commerce Dave Kerr said, "Our state's bioscience successes are getting the attention they deserve. In just the last year, Fort Dodge Animal Health and ...

Breakthrough Slashes $7 Corn Over Half for Cattle Feeders

... U.S. Ag, LLC of Luthersville, GA has the attention of cattle feeders and dairymen industry wide with the creation of a ... GA (PRWEB) June 24, 2008 -- U.S. Ag, LLC of Luthersville, GA has the attention of cattle feeders and dairymen industry wide with the creation of a ...

Boston Scientific Announces CEO Jim Tobin to Extend Tenure

... During the intervening time, Jim has devoted the majority of his attention to the integration of Guidant, while Paul has managed much of the ... potential of this business. The time is now right for Jim to turn his full attention and energies back to the core challenges facing the Company as a whole, ...

Shire Launches Nationwide Adult ADHD Mobile Awareness Tour

... the launch of a 13-city mobile screening initiative for adults with attention Deficit Hyperactivity Disorder (ADHD), a psychiatric disorder that affects ... the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies ...

Publication of Supplementary Prospectus

... dimesylate) supplementary New Drug Application for use in the treatment of attention Deficit Hyperactivity Disorder in adults, which was announced by Shire on ... the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies ...

Following a Good Start to the Year Shire Reaffirms Full Year 2008 Financial Guidance

... revenue growth through 2010." Product Highlights VYVANSE(TM) - attention Deficit and Hyperactivity Disorder ("ADHD") - By April 11, 2008 VYVANSE ... the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies ...

Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36%

... data at February 8, 2008 Product Highlights - VYVANSE(TM) - attention Deficit and Hyperactivity Disorder ("ADHD"). - Approved by the US Food ... the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies ...

Nanotech's health, environmental impacts worry scientists and the public

... agenda. Amplifying the problem is that the news media have not paid much attention to nanotechnology and its implications. In the long run, this ... research, they tend to agree with the public that they should pay attention to government regulations and unknown risks, she explained. Corley ...

Shire's ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome

... the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies ... products, including, but not limited to the impact of those on Shire's attention Deficit and Hyperactivity Disorder ("ADHD") franchise; patents, including ...

Study Examines Media Preferences of Life Scientists in Applied Markets

... growth in the traditional life science market, suppliers are turning their attention to opportunities in agricultural, biodefense and molecular diagnostics. ... markets. The report, "Marketing to Life Scientists: Capturing Customers' attention in Applied Markets" highlights the importance of effective marketing in ...

Novo Nordisk Applauds Adoption of World Diabetes Day Resolutions by U.S. Congress

... Frank Lautenberg (D-N.J.) and Norman Coleman (R-Minn.) to help focus attention on diabetes and make the disease a top national health care priority. ... Stabenow, Domenici, Lautenberg and Coleman, and the entire Congress. The attention and urgency these resolutions will bring to diabetes prevention and ...

Shire Divests Non-Core Product Portfolio to Almirall

... the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies ... products, including, but not limited to the impact of those on Shire's attention Deficit and Hyperactivity Disorder (ADHD) franchise; patents, including ...

Shire's ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome

... the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies ... products, including, but not limited to the impact of those on Shire's attention Deficit and Hyperactivity Disorder ("ADHD") franchise; patents, including ...

2007 Global Survey Identifies Characteristics of Supply Chain Leaders

... enhanced if those in the follower and laggard categories focus more attention on the lessons learned by the leaders -- especially in terms of increased ... "They can be especially helpful in supplying cost data and drawing attention to the ways improvements can enhance financial performance," said Poirier. ...

Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business

... the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies ... products, including, but not limited to the impact of those on Shire's attention Deficit and Hyperactivity Disorder ("ADHD") franchise; patents, including ...

IFRS Information - First Half of 2007

... the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies ... products, including, but not limited to the impact of those on Shire's attention Deficit and Hyperactivity Disorder ("ADHD") franchise; patents, including ...

Expiry of Hart-Scott-Rodino Waiting Period for JUVISTA(R) (Human TGF BETA 3)

... the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies ... products, including, but not limited to the impact of those on Shire's attention Deficit and Hyperactivity Disorder ("ADHD") franchise; patents, including ...

Viral Genetics Creates Subsidiary to Develop Cancer Therapy

... the knowledge and experience to take this program forward. Creating a new corporation dedicated to that effort is critical to give this science the attention it deserves. At the same time, it enables Viral Genetics to remain focused on its core mission of pursuing treatments for autoimmune diseases, in ...

Cadence Pharmaceuticals Reports Second Quarter 2009 Financial Results

... or Cadence's clinical trial sites, may raise issues that must be resolved prior to obtaining final approval of the NDA; the risk that increased attention to drug safety issues in general may result in a more cautious approach by the FDA, which could delay the completion of the review process for the ...

ETC Biomedical Announces Chamber Sale in India

... time management and paper recordkeeping while ensuring comprehensive documentation of the procedure. These features enable technicians to focus their attention on patient care and management, making your team more effective and efficient. ETC chambers remain the leader in providing a patient friendly ...

Revised: Sinovac Provides Update on Clinical Trial for H1N1 Vaccine Trials

... Disease Control (CDC), and undertaken by Beijing CDC. The Ministry of Health (MOH) and State Food and Drug Administration (SFDA) are paying close attention to this clinical trial. Deputy Director General of MOH Disease Control Department, Donglou Xiao, Director of SFDA Registration Section, Wei Zhang, ...

Sinovac Provides Update on Clinical Trial for H1N1 Vaccine Trials

... Disease Control (CDC), and undertaken by Beijing CDC. The Ministry of Health (MOH) and State Food and Drug Administration (SFDA) are paying great attention to this clinical trial. Deputy Director General of MOH Disease Control Department, Donglou Xiao, Director of SFDA Registration Section, Wei Zhang, ...

Purdue Pharmaceutical Products L.P. and Transcept Pharmaceuticals, Inc. Sign Exclusive Agreement to Commercialize Intermezzo(R) in the United States

... investment. Our agreement with Purdue establishes the potential for a substantial Transcept revenue stream, and now enables us to focus increasing attention on prospective Intermezzo ((R) )commercialization partners in other parts of the world. The increased resources Transcept receives from this ...